Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Subscribe To Our Newsletter & Stay Updated
